Glaxo (GSK), Human Genome's (HGSI) Benlysta Wins Backing of FDA Advisory Panel
Tweet Send to a Friend
Get Alerts GSK Hot Sheet
Price: $52.22 +0.21%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 4.8%
EPS Growth %: -35.7%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 4.8%
EPS Growth %: -35.7%
Trade GSK Now!
An FDA panel has recommended approval of GlaxoSmithKline (NYSE: GSK) and Human Genome Sciences (Nasdaq: HGSI) new lupus treatment Benlysta.
As the process goes (from effectiveness to safety to recommendation), the panel first found the drug effective in a 10-5 vote, then, in a 14-1 vote, found that Benlysta was safe. Finally, the panel voted 13-2 to back the lupus treatment.
Benlysta will be the first new lupus drug in more than 50 years.
While shares of Human Genome Sciences have been halted throughout today's trading session (on account of the FDA panel hearing), shares of the massive GlaxoSmithKline are up 2.7% in this evening's after-hours session.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
As the process goes (from effectiveness to safety to recommendation), the panel first found the drug effective in a 10-5 vote, then, in a 14-1 vote, found that Benlysta was safe. Finally, the panel voted 13-2 to back the lupus treatment.
Benlysta will be the first new lupus drug in more than 50 years.
While shares of Human Genome Sciences have been halted throughout today's trading session (on account of the FDA panel hearing), shares of the massive GlaxoSmithKline are up 2.7% in this evening's after-hours session.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
- Amid Tesla (TSLA) Squeeze, Option Prices Hit Record Highs
- Can AMD (AMD) Shake Off the Goldman Downgrade?
Create E-mail Alert Related Categories
FDA, Trader Talk
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
